Detection of doxorubicin in blood plasma using luminescent nanosensors
Koganova D.G., Tsupka D.V., Drozd D.D., Pidenko P.S., Mescheryakova S.A., Kornilov D.A., Goryacheva O.A., Goryacheva I.Yu.
Saratov State University
Abstract
The main drug treatment for oncology is chemotherapy. Doxorubicin (Dox) is a drug from the anthracycline antibiotic group, the use of which has a number of disadvantages, consisting in the effect on malignant and healthy cells, and also has high cardio-, cyto- and neurotoxicity. In this regard, it is necessary to constantly monitor the concentration of Dox in the patient's body. Several methods for the quantitative determination of Dox in body fluids and tissues are known, the most common approach is high-performance liquid chromatography (HPLC) with various types of detectors. Despite its widespread use, the HPLC method has a number of disadvantages. A simple, rapid method for determining Dox in blood plasma is presented, based on the quenching of luminescence of QD, which will allow it to be used to adjust chemotherapy. The effect of QD concentration in water and blood plasma was studied, the highest sensitivity to Dox was achieved with QD at an optical density of 0.05. To assess the effect of matrix components of blood plasma, several plasma dilutions were studied. The optimal dilution was 25 times, the detection limit was 0.02 µg/ml, the Stern-Volmer constant was 5.6 M-1, which is comparable with the values for determination in water. The results of Dox determination in human blood samples show that the developed method has good repeatability and accuracy. The reliability of the proposed method was confirmed by comparing the results with the HPLC-UV method.
The work was supported by the Russian Science Foundation (project 23-13-00380).
Speaker
Koganova Daria G.
Saratov State University
Russia
Discussion
Ask question
